An Analysis of CLL in Adolescents and Young Adults
An Analysis of CLL in Adolescents and Young Adults
This article was originally published on Docwire News
Most patients diagnosed with chronic lymphocytic leukemia (CLL) are older; the median age at diagnosis is 70 years. Less than 2% of patients are younger than 45 years. Previous research has not evaluated next-generation sequencing (NGS) gene mutation and novel oral therapies in adolescent and young adult (AYA) patients with CLL. A retrospective study evaluated disease characteristics that impact CLL outcomes in AYA patients. The data were presented at the 62nd ASH Annual Meeting & Exposition.
Between January 1, 2000, and December 31, 2019, 227 patients aged 15 to 39 years were diagnosed with CLL/small lymphocytic lymphoma at a single institution. Labs and Rai stage were recorded if available pre-treatment and within 12 months of diagnosis. Fluorescence in situ hybridization (FISH), cytogenetics, CD38, ZAP-70, gene mutations were collected from any time pre-treatment.
The median age at the time of diagnosis was 37 years (range, 17-39 years); from diagnosis, patients were followed for a median of 7.1 years (range, 0-19.3 years).
Among the 167 patients with available pre-treatment FISH data, 65 (39%) had del(13q), 26 (16%) had trisomy 12, 24 (14%) had del(11q), seven (4%) had del(17p), and 45 (27%) had no FISH abnormality. Among the 159 patients with available immunoglobulin heavy chain variable (IGHV) data, 82 (52%) had mutated and 77 (48%) unmutated IGHV. Only 3% of patients had a first-degree relative with CLL. The following rates of gene mutation were identified: TP53, 3% (n=2/59); NOTCH1, 18% (n=8/45); SF3B1, 16% (n=7/45); POT1, 9% (n=4/45); BIRC3, 7% (n=3/45); and MYD88, 11% (n=5/45). Outcomes could not be evaluated by mutation status because of the limited number of patients with available data.
Venclexta PBS listed as first line therapy for CLL patients unfit for chemotherapy
Venclexta PBS listed as first line therapy for CLL patients unfit for chemotherapy
This article was originally published on Mirage
- VENCLEXTA plus obinutuzumab is a combination, fixed duration therapy for previously untreated patients with CLL who are unfit for chemotherapy
- VENCLEXTA was developed out of the Australian discovery that a protein called BCL-2 helps CLL cells survive. Blocking this protein helps to kill and reduce the number of these cancer cells(1)
- Over 1,800 people are predicted to be diagnosed with CLL in Australia this year making it the most common type of leukaemia diagnosed in Australia
Monday 30 November 2020, Sydney – AbbVie (NYSE: ABBV) Australia has welcomed the Government’s announcement that Venclexta® (venetoclax) in combination with obinutuzumab will be available to eligible Australians with Chronic Lymphocytic Leukaemia (CLL) as a first line therapy via the Pharmaceutical Benefits Scheme (PBS) from the 1st December 2020. This PBS listing will allow CLL patients who cannot be treated with standard chemotherapy-based treatments to have affordable access to this first line combination treatment.
Venclexta in combination with obinutuzumab is a targeted, 12-month duration treatment that is to be reimbursed for patients with previously untreated CLL, who are unfit for conventional chemotherapy. (1,5)
Venclexta works by blocking a protein in the body (BCL-2) that helps these cancer cells survive. Blocking this protein helps to kill and reduce the number of cancer cells. It is an oral tablet that can be taken daily in combination with intravenous obinutuzumab.(1)
ASH 2020 CLL Daily Wrap-Up
ASH 2020 CLL Daily Wrap-Up
This article was originally published on Patient Power
Overview
Join Patient Power on Tuesday, December 8th at 4pm PT/7pm ET for a live recap of the latest chronic lymphocytic leukemia (CLL) news from the 62nd American Society of Hematology (ASH) Annual Meeting. ASH is the world’s most comprehensive hematology event of the year where experts review thousands of scientific abstracts, highlighting updates on the most critical topics in hematology. Some of the field’s top doctors will share their thoughts on emerging research, clinical trials, and how current events such as COVID-19 are impacting cancer patients. Attend live to hear exciting CLL news from ASH 2020!
This program is sponsored by Pharmacyclics. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
CLL Advocates NZ Newsletter Issue 6
CLL Advocates NZ Newsletter Issue 6
Friends of CLLANZ
Funding has been received, with thanks, from the BOP Medical Research Trust for a research project to be done as a summer studentship, by fifth year medical student, Andrew Weston, on “second primary malignancies in NZ CLL patients”.
Second primary malignancies are important in CLL, where the impaired immune system is not as able to deal to developing malignancies as people with normal immune systems can. As a consequence, about one third of CLL patients die of a second primary malignancy, such as melanoma, colon cancer, and pancreatic cancer. Some of these cancers have well-recognised screening procedures to detect early stage cancers, which can have a better outcomes to treatment then, compared to when they are picked up when symptoms develop.
Regular skin checks, and colonoscopy are two good examples of this screening approach.
I would be interested to hear from any of the CLLANZ Friends who are in this group i.e. have had a second primary malignancy, as it may help with the study.
I encourage you to spread the word about the existence of CLLANZ to any New Zealanders you know who are living with CLL, and encourage them to make contact with us.
The other request is to encourage you all to take an active approach to our Facebook group, and to continue to read HealthUnlocked and Patient Power newsletters , which are both easy groups to join, or can be read on our website.
A CLLANZ trustees meeting will be held this month, to review the year gone by, and to plan for the next twelve months. Please contact me at neil@clladvocates.nz to let me know about any topics you would like considered for the agenda.
Best wishes
Neil Graham
CLL Advocates NZ Newsletter Issue 5
CLL Advocates NZ Newsletter Issue 5
Friends of CLL Advocates NZ
I’m pleased to report on a very successful inaugural CLLANZ seminar on 14 October, co-hosted by LBC. Around 100 people attended either by zoom or in person in LBC offices up and down the country. There were three excellent presentations by three of NZ’s most authoritative clinicians on CLL. Dr Peter Browett described the disease, Dr Gillian Corbett spoke on therapy, and Dr Rob Weinkove explained likely future directions for CLL treatment. An informative panel discussion and questions session concluded the two-hour event.
I thank all those who helped organise and manage this event, and particularly LBC for providing their facilities. This will hopefully be the first of many such events in years to come.
The seminar has provided us with an up-to-date, comprehensive patient resource on CLL in NZ. A video of the full event will shortly be posted on our website, and the presentations can be found here.
Identifying the priorities we should be pushing for in CLL treatment was a key theme of the event. These included having testing available in NZ for IgVH mutations, and I’m pleased to say this has already stimulated momentum to develop this.
As well as being our inaugural seminar the event was the formal launch of CLLANZ, almost two years after we first discussed the idea of starting the group, somewhat delayed by COVID 19.
It was also the formal launch of our booklet “CLL – A Guide for Patients in NZ”. Again, dedicated individual and team effort resulted in an excellent, informative document, which is available here on our website and in hard copy. If you would like a hard copy please send us your postal address. The booklet is also being distributed to CLL clinics around NZ, where you can also pick up a copy. Feedback on this is welcomed.
We’ve already had a lot of positive feedback on the event, along with suggestions for future seminar themes, and would welcome further thoughts on this.
Best wishes
Neil Graham
Novel Prognostic Model Predictive of Survival in Ibrutinib-Treated CLL
Novel Prognostic Model Predictive of Survival in Ibrutinib-Treated Chronic Lymphocytic Leukemia
This article was originally published by Hematology Advisor
A 4-factor prognostic model may help to identify patients with chronic lymphocytic leukemia (CLL) at risk of ibrutinib failure, according to research published in the Journal of Clinical Oncology.
As CLL is a “clonal expansion of mature B cells drive by constitutive activation of B-cell receptor (BCR) signaling,” previous studies suggest that the selective inhibition of BCR and BCL-2 protein may significantly improve outcomes in some patients with CLL compared with chemotherapy as a first-line therapy.
Ibrutinib, a Bruton tyrosine kinase inhibitor, is frequently used in the CLL setting, though drug resistance invariably evolves, with relapse occurring often with ibrutinib monotherapy.
Identifying those at risk of relapse after ibrutinib therapy would improve treatment decision-making among patients with CLL. While there are existing prognostic indices, none specifically evaluate for criteria known to be linked with the evolution of ibrutinib resistance. In the present study, the researchers evaluated and validated the effectiveness of a 4-factor prognostic model among patients with CLL treated with ibrutinib.
CLL Advocates NZ Launches a New Zealand Patient Guide
CLL Advocates NZ Launches a New Zealand Patient Guide
CLL Advocates NZ is pleased to announce the official launch of its patient booklet, CLL – A Guide for Patients in New Zealand. It has been made available in both a digital download and as a hardcopy booklet.
The booklet is being launched at CLL Advocates NZ’s inaugural patient seminar in Auckland and online tonight (14 October). The seminar will discuss ‘What is the state-of-the-art treatment for CLL in New Zealand?’
The booklet was compiled by Leukaemia Care, a national UK blood cancer support charity. Leukaemia Care has kindly granted us permission to adapt the booklet for the New Zealand CLL setting, and to publish it here on our website, and make it available as a printed booklet for distribution in New Zealand. This agreement is in line with CLL Advocates NZ’s commitment to working closely with other CLL patient advocacy groups and to avoid duplicating available high quality work undertaken by others.
Adaptation of the booklet for New Zealand conditions has been undertaken by Gillian Corbett MBChB, FRACPath, MRCP, FRACP, haematologist and Trustee, CLL Advocates NZ, Neil Graham FRACP, FRCP, Executive Director, CLL Advocates NZ, and Catherine Isaac, Trustee, CLL Advocates NZ.
We are most grateful to Leukaemia Care for this very valuable contribution to our work.
To learn more about the booklet, download it, or to request a hardcopy click here.
CLL Advocates NZ Newsletter Issue 4
CLL Advocates NZ Newsletter Issue 4
Friends of CLL Advocates NZ
This month is Blood Cancer Awareness Month, so it was a good opportunity to reflect on collaboration, networking, and resource sharing between CLL Advocates New Zealand and other blood cancer patient support groups, which like us, are working to better understand and treat these disorders, and support those with them.
A recent and significant example of this is a current, and near complete, project of launching our ‘CLL Guide for Patients’ booklet. We have worked with and drawn upon the resources of Leukaemia Care, a national UK blood cancer support charity, to adapt their patient booklet for a New Zealand CLL setting. Within the next month CLLANZ will be launching this CLL patient guide. Leukaemia and Blood Cancer NZ (LBC) will also be launching an updated version of their own CLL booklet.
Education and learning are a major part of the way forward in your CLL journey, so I encourage you to access a copy of our booklet, which will be available in both hard copy and as a PDF download on our website. I’m sure you will find it an informative resource.
A lot of work has gone into the CLLANZ booklet, and I would like to thank Dr Gillian Corbett, Catherine Isaac, and Heather Phillips for their great work in putting the document together.
Following on from education and learning, the CLLANZ inaugural patient seminar is this coming month. Three of NZ’s experts on CLL will speak, followed by a panel discussion and questions. This is a joint event with LBC, at the LBC headquarters in Auckland, or on Zoom from anywhere, to be held on Wednesday 14 October. Registration and details can be found on our website here.
In support of other CLL patient support groups, I want to remind you of the resources and networking available globally including groups such as PatientPower and HealthUnlocked. These websites have a lot of useful information and their patient networks, while in a global setting, are very active. You can join the HealthUnlocked global community here, which boasts just under 16,000 members, and access the PatientPower CLL online events here.
There are also regular teleconferences, and other educational activities, which we have now started listing on our website here in a new events section. Many of these events are international webinars held at difficult times of the day for most of us here in New Zealand. So, we are working to access recordings of these to share with you to watch on-demand.
Another CLL group was also recently formed – Doctors with CLL, which I have joined. I will keep you posted on developments here. The umbrella organisation is CLLAN (CLL Advocates Network), based in Europe, and the organisers of the conference I attended in Edinburgh a year ago. CLLAN coordinates the activities of these groups, and there is a lot of information on their website.
There are a number of other activities also underway that I have shared recently, and which you hopefully you have in your diaries:
- Survey on participation in drug trials.
- Dr Karen Oldfield’s PhD research project questionnaire on medical marijuana use in NZ.
- Shared experiences within our group, of second malignancies that they have had in addition to their CLL.
Thank you to all of you who have been posting and engaging with material on our Private Facebook Group. Engagement from patients and supporters helps others feel confident about sharing their own stories, struggles and questions, so I encourage you to please use this platform to share resources, ask questions and comment and engage with one another. This activity will go on to help us grow the group.
Finally, the general election is this coming month. An important issue for CLL patients is funding of medications. I encourage you to look at the health policies of the significant parties and put attention on their position on Pharmac funding. A good website to look at all parties and their policies all at once is www.policy.nz. You can link directly to the health funding policies here.
Best wishes
Neil Graham
The CLLANZ Inaugural CLL Seminar
CLLANZ Inaugural Patient Seminar
What is the state-of-the-art treatment for CLL in New Zealand?
What are the latest international and local developments in CLL research and treatment, and what’s on the horizon? What is the optimal approach to ‘watch and wait’ management? How can we access clinical trials? How does New Zealand compare with international standards of care?
For answers to these questions and more, join us in person or online for the CLL Advocates NZ Inaugural CLL Seminar, featuring three of NZ’s top haematologists and CLL specialists Dr Rob Weinkove, Dr Peter Browett and Dr Gillian Corbett.
The format will be short presentations from each speaker followed by a panel discussion and Q&A. Attendees can send in questions in advance of the meeting or ask them in person either at the event or through the Q&A chat window on the live stream of the seminar. Questions you’d like to submit in advance can be emailed to TimM@leukaemia.org.nz
The event is co-hosted by Leukaemia & Blood Cancer New Zealand with three options to attend.
You can attend in person at LBC’s main office in Auckland, at your local LBC support centre (via Zoom live stream), or from the comfort of your home via Zoom live stream. See details below.
Patients and their supporters are welcome to attend. Please register for one of the following.
Presentations
Options to attend
Attend in person in Auckland at the live event
5.15pm – 7pm: 6 Claude Road, Epsom, Auckland
Register by phoning Tim Maifeleni on 0800 15 10 15 Extn 9217 or emailing TimM@leukaemia.org.nz by 7 October
Attend in person at your local LBC support centre
Live event will be screened via Zoom from 5.30pm
Register by calling your local support coordinator on 0800 15 10 15 or email info@leukaemia.org.nz by 7 October
From home (Via Zoom)
Live video from 5.30pm
Register to join the live Zoom meeting here
After you register you will receive a confirmation email
4 October - CLL Treatments Today: What Should I Know?
Online webinar: CLL Treatments Today: What Should I Know?
Virtual town meeting - 4 October 5am (NZST)
Overview
Join this virtual town meeting for chronic lymphocytic leukemia (CLL) patients and family members on Saturday, October 3, 2020 starting at 9 am PT/12 pm ET. This 3-hour program will take you through a CLL 101, 201 and 301 class hosted by CLL patient advocates and experts from Cleveland Clinic and University Hospitals Cleveland Medical Center. All attendees will receive a special Powerful Patient face mask.
We want you to be part of this event! Send us your best selfie, or a picture of you with your family, or a pet –anything that tells us who you are! You might just see it on the screen! Please send it to cll@patientpower.info. By sending it to us, you consent to its use in the CLL town hall recorded content and live stream.
Agenda
12:00-12:30 pm ET- CLL 101 – Information for the newly diagnosed. Learn about the stages of CLL, how to talk to your friends and family, and what to ask your doctor.
12:30-12:45 pm ET- CLL and COVID-19 – Is it safe to start or resume treatment right now? Find out how the coronavirus pandemic is impacting CLL patients.
12:45- 1:30 pm ET- CLL 201 – Learn about the current CLL landscape, including treatment options, side effects and the significance of minimal residual disease (MRD) testing.
1:30-1:45 pm ET – Break
1:45 -2:30 pm ET- CLL 301 – Experts discuss the future of CLL treatment, including FDA approvals, clinical trials and Richter’s Transformation.
2:30-3 pm ET – Q&A